Skip to main content

Table 2 Subgroup analysis of overall survival from available data

From: Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials

Subgroup

No. of studies

OS HR (95 % CI)d

Weight (%)

Heterogeneity within subgroup

Criteria

Characteristics

I 2 (%)

p value

Experimental drug

Azacitidinea

3

0.67 (0.56, 0.79)

48.3

0

0.38

Decitabine

2

0.86 (0.73, 1.02)

51.7

0

0.85

Subgroup difference

p = 0.04*

Cytogenetics riskb

Poor risk

3

0.75 (0.56, 1.00)

43.9

26

0.26

Intermediate risk

3

0.78 (0.40, 1.52)

37.0

65

0.06

Good risk

2

0.63 (0.42, 0.93)

19.0

0

0.64

Subgroup difference

p = 0.75

BM blast countc

More than 30 %

2

0.79 (0.68, 0.92)

48.9

0

0.32

Less than 30 %

3

0.82 (0.57, 1.18)

51.1

74

0.02

Subgroup difference

p = 0.85

Conventional care regimens

BSC only

2

0.76 (0.53, 1.10)

28.4

44

0.18

BSC and CTxe

3

0.73 (0.60, 0.90)

71.6

53

0.12

Subgroup difference

p = 0.85

  1. aOne study [25, 30] included only RAEB and RAEB-T for the HR analysis of OS
  2. bTwo studies [30, 32] did not report subgroup survival outcome data according to cytogenetic risk
  3. cOne study [30] did not report subgroup survival outcome data according to BM blast count (≥30 vs. <30 %)
  4. dHR value was extracted from subgroup analysis data of individual trial
  5. eCTx includes low dose cytarabine and intensive chemotherapy
  6. *Statistically significant